The results in figure 2a–c show that at a physiologic dose of 10 nM, CCL5 increases glucose uptake for all three breast cancer cell lines and that this uptake is CCR5- and mTOR-dependent, as both maraviroc (CCR5 inhibitor) and rapamycin (mTOR inhibitor) inhibit uptake. Here, CCL5 is linked to breast carcinoma.